Effects of Tildrakizumab on Epigenetic Age

Clinical trial NCT05110313 · COMPLETED

Trial details

NCT number: NCT05110313
Sponsor: Carlos Wambier
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Psoriasis Aging Epigenetic Disorder Inflammation; Skin

Start date: 2022-04-08
Primary completion: 2024-05-24
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.